Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia
暂无分享,去创建一个
Maria Grazia Valsecchi | Barbara Buldini | Giuseppe Basso | Richard Ratei | Leonid Karawajew | Angela Schumich | Andrea Biondi | Giovanni Cazzaniga | Daniela Silvestri | M. Schrappe | M. Valsecchi | G. Basso | R. Panzer‐Grümayer | W. Ludwig | L. Karawajew | D. Silvestri | A. Schrauder | A. Biondi | G. Cazzaniga | B. Buldini | M. Dworzak | V. Conter | A. Schumich | Giuseppe Gaipa | Marinella Veltroni | Oscar Maglia | Wolf-Dieter Ludwig | Martin Schrappe | G. Gaipa | R. Ratei | Valentino Conter | Michael N. Dworzak | M. Veltroni | Renate Panzer-Grümayer | Alessandra Benetello | T. Villa | Simona Sala | Andre Schrauder | Tiziana Villa | O. Maglia | S. Sala | Alessandra Benetello | R. Panzer-Grümayer | Richard Ratei | Wolf-Dieter Ludwig
[1] D. Printz,et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow , 1997, Leukemia.
[2] M. Björkholm,et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping , 2004, Leukemia.
[3] T. Klingebiel,et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL , 2002, Leukemia.
[4] D. Campana,et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR , 2005, British journal of haematology.
[5] D. Campana. Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.
[6] M. Schrappe,et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting , 2007, Leukemia.
[7] R. Stallings,et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time‐points reveals high levels of concordance between molecular and immunophenotypic approaches , 2009, British journal of haematology.
[8] Giuseppe Basso,et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. , 2003, Haematologica.
[9] A Orfao,et al. New methodologic approaches for immunophenotyping acute leukemias. , 2001, Haematologica.
[10] Michael N Dworzak,et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.
[11] F. Behm,et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia , 1999, Leukemia.
[12] Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .
[13] W. Kamps,et al. Regenerating normal B‐cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease , 2000, British journal of haematology.
[14] J. Hancock,et al. Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia , 1998 .
[15] L. Foroni,et al. INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSIS , 1999, British journal of haematology.
[16] B. Schäfer,et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.
[17] Pui,et al. Childhood Acute Lymphoblastic Leukemia. , 1997, The oncologist.
[18] J. V. van Dongen,et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.
[19] H. Cavé,et al. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .
[20] A. Órfão,et al. Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.
[21] J. V. van Dongen,et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. , 1995, Leukemia.
[22] J M Bland,et al. Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .
[23] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[24] H. Gadner,et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.
[25] G. Basso,et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection , 2005, Leukemia.
[26] D. Campana,et al. Detection of minimal residual disease in acute leukemia by flow cytometry. , 1999, Cytometry.
[27] Maria Grazia Valsecchi,et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] G. Basso,et al. Expression of CD 58 in normal , regenerating and leukemic bone marrow B cells : implications for the detection of minimal residual disease in acute lymphocytic leukemia , 2003 .
[29] A. Órfão,et al. BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL) , 2000, Leukemia.
[30] D. Campana,et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.
[31] Andrea Faini,et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B‐cell precursor acute lymphoblastic leukemia cells , 2008, Cytometry. Part B, Clinical cytometry.
[32] S. Hunger,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.
[33] A. Morley,et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.
[34] J. V. van Dongen,et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.
[35] F. Behm,et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.
[36] A. Órfão,et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL , 1999, Leukemia.
[37] C. Eckert,et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia , 2001, The Lancet.
[38] M. Borowitz,et al. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group , 2005, Cytometry. Part B, Clinical cytometry.
[39] Giuseppe Basso,et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible , 2008, Cytometry. Part B, Clinical cytometry.
[40] G. Basso,et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease , 2004, Leukemia.
[41] D. Campana,et al. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.
[42] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.